Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.21 | 2e-09 |
mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.19 | 4e-08 |
mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | 0.21 | 2e-06 |
mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | 0.17 | 4e-06 |
mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.17 | 4e-06 |
mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | 0.14 | 1e-05 |
mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.15 | 3e-05 |
mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | 0.15 | 4e-05 |
mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | 0.13 | 4e-05 |
mRNA | CHEMBL1222381 | CTRPv2 | pan-cancer | AAC | 0.14 | 5e-05 |